Enliven Therapeutics Q1 2023 Earnings Report
Key Takeaways
Enliven Therapeutics reported a net loss of $14.7 million for the first quarter of 2023. The company's cash and cash equivalents totaled $292.1 million as of March 31, 2023, expected to fund operations into early 2026.
Successfully completed merger with Imara Inc., trading under the new ticker symbol on Nasdaq, “ELVN”.
Dosed first patient in Phase 1 study of ELVN-002 in patients with HER2-altered non-small cell lung cancer (NSCLC) and other solid tumors.
Enrollment progressing in Phase 1 trial with ELVN-001 in chronic myeloid leukemia (CML).
Ended the first quarter 2023 with cash and cash equivalents of approximately $292 million, which is expected to provide cash runway into early 2026.
Enliven Therapeutics
Enliven Therapeutics
Forward Guidance
The company expects to share initial safety and efficacy data from the Phase 1a study in 2024 for both ELVN-001 and ELVN-002 programs.